Editorial correspondence

What we can answer

Editorial correspondence is welcome. The kinds of message we are best placed to respond to: corrections to a numerical figure, a missing citation, a broken link, a misattributed study, a request to clarify how a particular trial is summarized on the site, or a suggestion for a new publication to add to the index. If you are a researcher whose work is cited here and you would like to flag a correction or update, please do.

What we cannot answer

We cannot give medical advice. We cannot answer questions about whether tirzepatide is right for an individual reader, what dose someone should use, how to obtain a prescription, what to do about a side effect, or any other clinical question. Those questions are appropriately addressed to a licensed prescribing clinician — a primary care physician, an endocrinologist, an obesity medicine specialist, or another appropriately trained clinician with access to the reader's medical history.

We also do not respond to vendor solicitations, sponsorship pitches, link-exchange requests, guest-post offers, or marketing outreach. Our editorial position is independent and is intended to remain so.

Contact form

Please use the form below to send editorial correspondence. Mark the subject line with a short descriptor — 'CITATION QUERY', 'CORRECTION', or 'GENERAL' is helpful. Replies, when offered, are sent from a no-reply address; we do not engage in extended back-and-forth on clinical questions for the reasons noted above.

Notice

The content of this site is not medical advice. Tirzepatide is an FDA-approved prescription medicine; questions about its clinical use are appropriately addressed to a licensed prescribing clinician. Med Tirzepatide is an independent editorial pharmacopoeia — not a clinic, not a vendor, not a dispensary.